Navigation Links
End in Biological Technology

Sanofi-aventis Announces Second Quarter 2009 Results

... of Zentiva in the second quarter, and the end of commercialization of Copaxone(R) by ... ((R)) were up 16.5% at euro 118 million. The end of commercialization of this product by ... half as a whole, net sales were flat due to the end of commercialization of Copaxone((R)) by ...

Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36%, Sales Increase 16%

... at April 30, 2009, up from $15.9 million at the end of the prior year. Cash on hand at the end of the year was $4.0 million, as compared to $4.3 million at the end of the prior year. Bank borrowings and capital ...

Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update

... July 31, 2009 but is now not expected before the end of Helix's fiscal 2010 first quarter ending ... that patient enrolment will be complete by the end of Helix's first fiscal quarter 2010. ... 23,636 23,263 19,057 11,379 end of the period 19,598 21,274 ...

AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer

... of 150 mg perifosine daily or placebo. After end of radiotherapy, patients were followed up to ... of recurrence or progression 12 months after the end of treatment. The study was planned under the ... in a 35% local control rate, one year after end of therapy in the placebo group. It was ...

Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients

... (four weeks on Zerenex): At the end of the treatment period (after four weeks on ... daily dose of Zerenex (ferric citrate) at the end of four weeks of treatment was 6.8 grams per day. ... serum phosphorus was 7.0 (1.1) mg/dL, and at the end of treatment with Zerenex the mean (SD) serum ...

Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions

... 170.5 171.8 145.1 Mean FPG at end of treatment (mg/dL) ... -42.0 -28.8 Change in 2-hr PPG at end of treatment (mg/dL) -8.8 ... 7.67 7.90 7.45 7.38 % HbA1c at end of treatment 7.15 7.28 7.00 ...

China Biologic Products Announces Strong First Quarter 2009 Results

... current ratio of 1.0. Shareholder's equity at the end of the first quarter of 2009 was $39.9 million, compared to $37.2 million at the end of 2008. The Company generated $7.1 million in ... 8,814,616 5,010,033 CASH, end of period $34,005,948 ...

ThromboGenics NV: Business Update

... trial are expected to be presented towards the end of 2009. TB-402 - Long acting ... anticipated that this study will conclude by the end of 2010. TB-403 - Anti-cancer: Partnership ... well - Phase Ib trial results expected by the end of 2009. In June 2008, ThromboGenics and its ...

Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market

... of achieving positive operating cash flow by the end of 2010, while continuing to position the company ... expenses for 2009 will now be at the lower end of the previously stated guidance range of $600 ... and GAAP operating loss will also be at the lower end of the previously stated guidance range of $175 ...

BioMarin Announces First Quarter 2009 Financial Results

... companies will be written down to zero by the end of the year. 2009 Guidance All ... Please see the table provided at the end of this press release for a full ... income is detailed in the table provided at the end of the press release. BioMarin believes that ...

Caliper Life Sciences Reports First Quarter 2009 Results

... revenues of $28.5 million exceeded the top end of its guidance of $25 to $28 million. The ... as the primary reason for exceeding the top end of its guidance range. Key revenue ... Statements of Operations is provided at the end of this release under "Adjusted Consolidated ...

Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R)

... data on all 200 randomized patients at the end of June. "We are pursuing this approach and ... the FDA. An interim analysis conducted at the end of 2008 for the primary endpoint demonstrated ... 2008, Thoratec received approval from the FDA to end randomization in the trial, based on a ...

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results

... the American Society of Hematology, with a year end update that coincided with the 27th Annual J.P. ... the American Society of Hematology, with a year end update that coincided with the 27th Annual J.P. ... Gynecologic Cancer Society, with a year end update that coincided with the 27th Annual J.P. ...

WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results

... in Jinshan with the intent of opening it by the end of 2009. We expect this facility to generate ... 2008. AppTec, which we acquired at the end of January 2008, contributed $15.1 million of net ... PharmaTech acquired AppTec, Inc. at the end of January 2008, and our reported results for ...

BioMS Medical Announces 2008 Year End Results

... the study reaching its primary endpoint at the end of the trial. Based on the DSMB ... on an un-blinded basis to the end of their 27th month in the trial. Licensing ... -------- Cash and cash equivalents - end of period 87,826 ...

Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results

... - Year end cash position improved through non core ... "We were pleased to achieve the high end of our revenue guidance for the quarter and ... quarter revenue of $36.7 million met the top end of its guidance estimate provided on November 10, ...

Spectral announces 2008 financial results

... Toray was signed subsequent to the year end on March 6, 2009. - Presented findings ... ---------------------------- Deficit - end of year (4,189) ... ---------------------- Cash - end of year ...

Martek Announces First Quarter 2009 Financial Results

... sales being more heavily weighted towards the end of the first quarter of fiscal 2009 as compared ... in first quarter of fiscal 2009. As of the end of the first quarter, Martek had $107.3 million ... 16,973 Cash and cash equivalents, end of period $107,309 $22,145 ...

ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results

... with Allergan and extension until end 2011 2008 Key events - Appointment of a ... healthy with more than 24 months of cash at the end of 2008 and a tool to strengthen our ... the warrant exercise period running until the end of June." - Income Statement Total ...

Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring

... leukemia dose escalation trial data by end of Q2 2009 -- Announce TRU-016 Phase 2a ... leukemia expanded cohort trial data by end of Q4 2009 -- Disclose next investigational new drug candidate by end of Q2 2009 for application in 2010 -- ...

Gentiva Reports Fourth Quarter and Fiscal 2008 Results

... Days sales outstanding (DSO) at 2008 fiscal year end was 57 days compared with 61 days at the end of the third quarter. Full-Year 2009 ... ------ Cash and cash equivalents at end of year $69,201 $14,167 ...

Yongye Biotechnology International to Expand its Network of Branded Stores

... of Yongye branded stores to over 1,125 by the end of the quarter. The Company anticipates having 2,000 Yongye branded stores by the end of 2009. The Company does not own any of ... and support needed to link the Company to its end users. Underscoring the importance of the ...

Pharmasset Reports Fiscal First Quarter 2009 Financial Results

... equivalents and short term investments at the end of the fiscal first quarter. Total costs and ... and pharmacokinetics in healthy volunteers at the end of the first calendar quarter of 2009; -- On ... enrollment of clevudine registration trials at end of first quarter of 2009; -- Initiate Phase 1 ...

Multisol France on Track to Sell 250 Tons of International Fuel Technology, Inc. Fuel Additive Formulations

... for resale into retail markets. The high level of end user demand and re-buy rates for these products ... we are realizing is a clear indication of the end user benefits IFT products provide," said ... companies with established marketing channels and end user accounts," said Axel Farhi, IFT's ...

Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities

... the Company to be cash flow positive by the end of 2010. The news was presented by Daniel M. ... achieving positive operating cash flow by the end of 2010 Bradbury added, "Our ... expenses to achieve positive cash flow by the end of 2010." A recording of the presentation is ...

PETLinQ Launches RISLinQ 4.0Mac on Mac OS X Platform

... the Mac platform. RISLinQ(R) 4.0Mac provides full end to end workflow capability for radiology facilities ... radiology community who desire an integrated end ...

China Biologic Products Reports Strong Third Quarter 2008 Results

... its dividends back into Shandong Taibang at the end of the 2007 fiscal year. The tax rebate was ... current ratio of 2.2. Shareholder's equity at the end of the third quarter of 2008 was $34.5 million compared to $22.4 million at the end of 2007. The Company generated $14.7 million net ...

China-Biotics, Inc. Reports Second Quarter 2009 Financial Results

... $25 million of which is to be paid by the end of the third quarter of fiscal 2009. The ... in preparation for the plant coming online at the end of this calendar year. With limited capacity in ... CASH AND CASH EQUIVALENTS BALANCES AT end OF PERIOD $65,633,495 ...

BMP Sunstone Reports Third Quarter 2008 Financial Results

... The Company expects to launch the product at the end of the fourth quarter of 2008. On July 18, ... to expect to complete the transaction by the end of the fourth quarter of 2008. Terms of the ... please see the non-GAAP data included at the end of this release. This data has more details of ...

ThromboGenics N.V.: Business Update

... in eye disease following a successful end of Phase II Meeting with the FDA. The recent ... back of the eye disease, following a successful end of Phase II meeting with the FDA. The ... to begin its Phase II clinical development by the end of 2008. ThromboGenics will provide a further ...

Amicus Therapeutics Announces Third Quarter 2008 Financial Results

... we remain on track to provide an update by the end of the year. In our Gaucher and Pompe disease ... Agency (EMEA) and will provide an update by the end of the year. A final decision on the global ... Amicus leads development operations through the end of Phase 2 clinical trials. The companies then ...

ev3 Inc. Reports Third Quarter 2008 Financial Results

... equivalents balance was $45.9 million as of the end of the third quarter of 2008, an increase of $7.2 million compared to the end of the second quarter of 2008. This increase ... cash and cash equivalents balance compared to the end of the second quarter of 2008. For the remainder ...

BioMed Realty Trust Reports Third Quarter 2008 Financial Results

... at the building to nearly 80% at the end of the quarter -- Executed leasing transactions ... FFO and a definition of FFO are included at the end of this release. Financing Activity As of ... 11,785,622 Following the end of the quarter, on October 3, 2008, a portion of ...

Genmab Announces Results for the First Nine Months of 2008

... of DKK 1.6 billion (USD 306 million) from the end of 2007. The decrease primarily arises from the ... that the operating loss will be at the lower end of the prior guidance of DKK 850 to 950 million. ... facility in Minnesota will lead to a year end cash position of DKK 1.7 to 1.8 billion, ...

Shire's New Product Portfolio Delivers Strong Quarterly Performance

... are in a strong position as we look ahead to the end of 2008 and beyond, with an excellent portfolio ... for net sales of VYVANSE for 2008 was the lower end of a range of $350 to $400 million. We have ... plans to provide a complete response by the end of the year. JUVISTA(R) - Improvement of scar ...

Accuray Reschedules Announcement of Results for First Quarter of Fiscal 2009

... periods. Of the $644 million in backlog at the end of the quarter, 70 percent consisted ... Accuray's cash and investment balances at the end of the quarter totaled $162.1 million, which ... long-term investments of $38.0 million. At the end of the first quarter the company continued ...

Helix BioPharma Corp. Announces Fiscal 2008 Results

... a Phase I IND filing to occur sometime before the end of Helix's fiscal fourth quarter ending July 31, ... IND/CTA filings for LSIL to occur before the end of the Company's fiscal fourth quarter ending ... ------------------------ end of the year 19,057 11,379 4,392 ...

Neurocrine Biosciences Reports Third Quarter 2008 Results

... respectively. The Company expects to end 2008 with approximately $100 million in cash and ... patients should be available at the end of the first half of 2009. Neurocrine is also ... The Company met with the FDA in July for an end of review meeting related to the December 12, ...

Boston Scientific Announces Results for Third Quarter Ended September 30, 2008

... use of these non-GAAP measures is provided at the end of this document. ... use of these non-GAAP measures is provided at the end of this document. ... use of these non-GAAP measures is provided at the end of this document. ...

Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%

... sub-cutaneous route). Cumulative 9-month sales at end September grew by 17%, the same growth rate as in ... registered a 5% year-on-year decline at end September, confirming the Company's strong ... Grasses for adults took place in Germany at the end of July. The product was well received by ...
Other Contents
(Date:8/29/2014)... understand how the repeated climatic shifts over the ... of genetic diversity, a team of researchers led ... Ana Carnaval developed a new biodiversity metric called ... which the genetic variation within species is restricted ... professor of biology, and 14 other researchers from ...
(Date:8/29/2014)... - In a cell,s nucleus, chromosomal DNA is ... an amalgam biologists call chromatin. Until about two ... "sidekick," the mere packing material around which the ... have developed a greater appreciation for how DNA/histone ... from multiple research institutions studying the sequence of ...
(Date:8/28/2014)... identified a handful of bacterial culprits that may drive ... ulcerative colitis, using patients, own intestinal immune responses as ... in the journal Cell . , Trillions of ... a critical role in the development and progression of ... of bacterial species affect a person,s susceptibility to IBD ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3Yale study identifies possible bacterial drivers of IBD 2
(Date:8/30/2014)... 30, 2014 According to Bloomberg ... that requires Takeda Pharmaceutical Co. and Eli Lilly & ... claims that the drugmakers concealed information about a risk ... The case, Allen v. Takeda Pharmaceuticals North America Inc. ... District of Louisiana (Lafayette).* , According to Bloomberg, Takeda ...
(Date:8/30/2014)... 2014 United Theological Seminary is pleased to ... the Master of Theological Studies (MTS). , ... designed for students who wish to pursue further academic study ... to serve the Church and community. Previously, students needed to ... can attend classes from any location where there is an ...
(Date:8/30/2014)... August 30, 2014 Daily Gossip magazine ... keeps anxiety and panic attacks under control with a ... program review describes this new method as an ... panic attacks and overcome general anxiety related disorders. ... is the fact that it can be accessed by ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 RB SEO ... cost SEO service for small businesses. , RBSEO Services ... cannot afford costly search engine optimization service. So, the ... small businesses into account. , On being asked ... have introduced this low cost SEO service because many ...
(Date:8/30/2014)... a common problem millions of American cope with every day. While ... for some, it can have a crippling impact on social activity ... mood swings and depression. , Those struggling with acne are ... some cases, that can make the problem even worse. Instead of ... quest for clearer skin can now view acne treatment reviews ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Decision to Uphold $9 Billion Actos Award 2Health News:United Theological Seminary Announces First Fully Online Degree 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:Acne Treatment Reviews Added to Popular Treatment Website 2
Other TagsOther Tags